Bdparib Tablet (Rucaparib) is a targeted cancer therapy belonging to the class of PARP inhibitors, primarily prescribed for the treatment of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with certain genetic mutations. It works by blocking the PARP enzyme, preventing cancer cells from repairing themselves, thereby slowing their growth. For detailed medical guidance, visit Mayo Clinic or Drugs.com.

Key Benefits & Uses

• Helps control the growth of ovarian, fallopian tube, and peritoneal cancers.

• Can be used as a maintenance therapy to delay cancer progression.

• Provides a targeted treatment option for patients with BRCA mutations.

• Oral administration makes it more convenient compared to intravenous chemotherapy.

For more medical research and peer-reviewed studies, you may explore PubMed and MedlinePlus.

How to Use

• Take Bdparib Tablet exactly as prescribed by your doctor.

• Swallow whole with water, with or without food.

• Do not crush or break the tablet.

• Maintain a regular schedule to maximize effectiveness.

• In case of missed dose, consult your doctor before resuming.

You can refer to dosage and prescription details from trusted sources like the FDA and WebMD.

Important Safety Information

• Inform your doctor about any liver, kidney, or blood disorders before use.

• Avoid during pregnancy or breastfeeding unless strictly advised.

• Regular blood tests may be required to monitor side effects.

• Do not self-medicate or change the dosage without medical supervision.

For global healthcare guidance, visit WHO and Healthline.

Common Side Effects

• Nausea, vomiting, and loss of appetite

• Fatigue and weakness

• Low blood cell counts (anemia)

• Abdominal pain or constipation

• Changes in liver function tests

If side effects persist or worsen, contact your healthcare provider immediately.

Why Choose Bdparib Tablet (Rucaparib)?

Bdparib Tablet is a clinically proven PARP inhibitor that provides hope to patients battling ovarian and related cancers. It offers targeted therapy designed to specifically attack cancer cells while sparing most healthy ones. Backed by research from FDA, PubMed, and clinical resources like WebMD, it remains a trusted choice for oncologists worldwide.